Will Insurance or a Government Scheme — Pay for Olaparib?

PM-JAY reimburses hospitals for listed cancer treatment packages — procedures, surgeries, inpatient chemotherapy. Olaparib is taken as daily tablets at home rather than administered in a hospital setting, so it does not fit the inpatient package model the scheme was built on. Your enrolment is valid; the scheme simply was not designed to cover outpatient oral medicines. Ask your oncologist whether any part of your olaparib treatment involves a hospitalisation episode that could be claimed under a listed package, and separately ask about manufacturer access programmes or whether a generic formulation would reduce your out-of-pocket cost.

Open your policy document and search for the terms 'oral chemotherapy', 'targeted therapy', 'oral anti-cancer drugs', or 'outpatient cancer medication'. Policies issued in the last few years are more likely to include these clauses than older policies, because insurers updated their products as oral targeted therapies became more common. If you cannot find those terms, call your insurer's helpline and ask specifically whether olaparib — a PARP inhibitor taken orally for cancer — is reimbursable under your plan. Ask for a written answer, not just a verbal one. If it is covered, request a pre-authorisation letter before filling the prescription.

Generic formulations of olaparib have received CDSCO approval and are available in India at substantially lower cost than the branded product Lynparza. Your oncologist can advise whether a generic is appropriate for your specific treatment plan and prescribe accordingly. Do not switch between brands or between branded and generic on your own — always discuss it with your treating team first, as they need to monitor your response to treatment consistently. The availability of specific brands varies by region and over time, so ask at your CION centre about what is currently accessible.

Pharmaceutical manufacturers sometimes run programmes that provide a medicine at reduced cost or free of charge to patients who cannot afford it. These programmes are not advertised publicly, and eligibility conditions vary — they typically consider income, whether a patient has insurance that has already been exhausted, and whether a specific programme is currently open for enrolment. The best way to access them is through your oncologist or CION's patient services team, who can check on your behalf and help with the application. Do not attempt to apply through unofficial third-party agents or websites claiming to facilitate these programmes.

Yes. CION's patient services team can assist with the documentation that insurers and schemes commonly require, including letters of medical necessity, treatment plans, and investigation reports. Your oncologist provides the clinical content; the team can guide you on the format and supporting documents different schemes or insurers ask for. Starting this process before your first prescription is filled — rather than after a claim has already been rejected — significantly reduces delays. Bring your policy document or scheme card to your first appointment so the team can advise on the specific requirements that apply to you.

Yes. You have the right to appeal an insurance denial in writing. Send a formal letter citing your policy number, the reason for denial as stated by the insurer, and a letter from your oncologist explaining the medical necessity and the CDSCO-approved indication. If the insurer upholds the refusal, you can escalate to the IRDAI ombudsman, which handles disputes between policyholders and insurers at no cost to you. Keep copies of every communication. An appeal is more likely to succeed when the refusal is based on a policy exclusion that does not clearly apply to oral targeted therapy — ask your oncologist to address this explicitly in their supporting letter.